CoChat

Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors

Open access
Mosher, Catherine E., Secinti, Ekin, Johns, Shelley A., Kroenke, Kurt, Rogers, Laura Q. · 2022 · Journal of Patient-Reported Outcomes

The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index; 3 of the 39 sources its claims cite were checked for support.

Abstract

BACKGROUND: Fatigue is a highly prevalent and disabling symptom in cancer survivors. Although many measures have been developed to assess survivors' fatigue, their ability to accurately capture change following intervention has rarely been assessed in post-treatment survivors. Ultra-brief fatigue measures are preferable in clinical practice but have limited evidence supporting their use with cancer survivors. We examined the psychometric properties of four Fatigue Symptom Inventory (FSI) measures, including the new FSI-3, in cancer survivors. Examined properties included responsiveness to change and minimally important differences (MIDs). METHODS: We analyzed data from three randomized controlled trials with post-treatment cancer survivors (N = 328). Responsiveness to change was evaluated by comparing standardized response means for survivors who reported their fatigue as being better, the same, or worse at 2-3 months. Responsiveness to intervention was assessed via effect sizes, and MIDs were estimated by using several methods. We also computed area under the curve (AUC) values to assess FSI measures' discriminative accuracy compared to an established cut-point. RESULTS: All FSI measures differentiated survivors who reported improvement at 2-3 months from those with stable fatigue, but did not uniformly differentiate worsening fatigue from stable fatigue. Measures showed similar levels of responsiveness to intervention, and MIDs ranged from 0.29 to 2.20 across FSI measures. AUC analyses supported the measures' ability to detect significant fatigue. CONCLUSIONS: Four FSI scales show similar responsiveness to change, and estimated MIDs can inform assessment of meaningful change in fatigue. The FSI-3 shows promise as an ultra-brief fatigue measure for survivors.

Overview

CoChat Summary

## TL;DR

This study evaluated four Fatigue Symptom Inventory (FSI) measures, including a new ultra-brief FSI-3, in 328 post-treatment cancer survivors from three randomized controlled trials. The FSI measures showed similar responsiveness to change, and the FSI-3 showed promise with a preliminary cut-point of mean score ≥ 5.

## Key findings

  • In three RCTs with post-treatment cancer survivors (N = 328), all FSI measures differentiated survivors who reported improvement at 2–3 months from those with stable fatigue, but they did not uniformly differentiate worsening fatigue from stable fatigue.
  • For responsiveness to change, the BEAT Cancer trial showed significant differentiation for all FSI measures between Worse and Same groups and between Better and Same groups, with SRMs ranging from 0.69 to 0.95 and from -0.78 to -0.96, respectively; in the MBSR trials, all FSI measures significantly differentiated Better from Same groups with SRMs from -0.88 to -1.13, but not Worse from Same.
  • MID estimates on the 0 to 10 FSI scales ranged from 0.90 to 1.69 using the global change anchor; coefficient of repeatability ranged from 1.10 to 2.20; 0.5 SD ranged from 0.73 to 1.10; and 2 SEM ranged from 0.79 to 1.59.
  • AUC values for distinguishing clinically significant fatigue at baseline ranged from 0.64 to 0.88, with 7 of 8 values being 0.74 or higher; for the FSI-3, a preliminary cut-point of mean score ≥ 5 gave sensitivity 0.77 and specificity 0.87.

## Methods

  • Data came from three randomized controlled trials with post-treatment cancer survivors (N = 328): two mindfulness-based stress reduction (MBSR) trials and the BEAT Cancer physical activity trial; baseline and first follow-up data were used.
  • The paper compared four fatigue measures: FSI severity, FSI interference, FSI total, and the derived 3-item FSI-3; SF-36 Vitality served as the anchor for responsiveness and ROC analyses.
  • Main analyses included standardized response means (SRMs), between-group effect sizes, MID estimation using several methods, and ROC/AUC analyses relative to an SF-36 Vitality cut-point of ≤ 45.

## Limitations

  • The paper states that the samples primarily consisted of non-Hispanic White women who had completed primary treatment for early-stage breast cancer, limiting generalizability to more diverse cancer populations.
  • It states that the MBSR trial sample sizes were relatively small, limiting statistical power and analysis of specific racial or ethnic groups.
  • It states that SF-36 Vitality was the only anchor used for responsiveness to change and AUC, had a different time frame than the FSI, and there is no criterion standard for fatigue responsiveness; it also notes that the 3-category MID approach may overestimate MIDs and that FSI-3 findings, including the cut-point and sensitivity to change, warrant replication.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s41687-022-00488-1

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

2 Valid · 0 Not valid · 17 Not checked · 38 Own results and interpretations

30 more claims

Create a free account to see all 57 claims and to verify the 36 references still open.

See all claims — free account
  • It may state two separate claims as one. 13
  • Probably not a substantial claim. 12

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 76 references

Cited by

See all 14

Metadata

Authors
Mosher, C. E., Secinti, E., Johns, S. A., Kroenke, K., & Rogers, L. Q.
Affiliations
  • Indiana University – Purdue University Indianapolis (US)
  • Regenstrief Institute (US)
  • University of Alabama at Birmingham (US)
Corresponding author
Mosher, Catherine E.
Venue
Journal of Patient-Reported Outcomes
Published
2022-07-23
Volume
6
Issue
1
Pages
82-82
ISSN
2509-8020 (ISSN-L)
OpenAlex
W4286716094
Cited by
14
References
77
Citations by year
2026: 1 · 2025: 8 · 2024: 3 · 2023: 2
FWCI
1.36
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Patient-Reported Outcomes (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by)
  • Purdue University Indianapolis (Indiana University) (submittedVersion, cc-by)
Funders
  • National Cancer Institute (R25CA117865, R01CA136859)
  • Walther Cancer Foundation (0106–01)
  • Indiana Clinical and Translational Sciences Institute (TR000163, TR000006)
Topics
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Childhood Cancer Survivors' Quality of Life
  • Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Keywords
cancer survivorship, cancer-related fatigue, responsiveness to change, minimally important difference, psychometric properties, standardized response mean, area under the curve, fatigue analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors. https://app.cochat.ai/papers/10.1186/s41687-022-00488-1
The paper
Mosher, C. E., Secinti, E., Johns, S. A., Kroenke, K., & Rogers, L. Q. (2022). Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors. Journal of Patient-Reported Outcomes. https://doi.org/10.1186/s41687-022-00488-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.